10-Q: Viking Therapeutics Advances Obesity and NASH Pipelines with VK2735 Entering Phase 3 and Strong VK2809 Histologic Data

Viking Therapeutics reported significant progress in its clinical pipeline, initiating Phase 3 trials for its obesity drug VK2735 and revealing positive 52-week histologic data for its NASH candidate VK2809, alongside increased R&D expenses and a strong cash position.

Summary

• Viking Therapeutics is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, with no revenue generated to date.
• The company reported a net loss of $65.561 million for the three months ended June 30, 2025, compared to $22.250 million for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $111.190 million, up from $49.606 million in the prior year period.
• Research and development expenses increased by 153.1% to $60.153 million for the three months ended June 30, 2025, and by 112.1% to $101.543 million for the six months ended June 30, 2025, primarily due to increased clinical study and manufacturing costs.
• General and administrative expenses rose by 40.2% to $14.421 million for the three months and 40.7% to $28.500 million for the six months ended June 30, 2025, mainly due to higher stock-based compensation.
• Cash, cash equivalents, and short-term investments totaled $807.7 million as of June 30, 2025, providing sufficient capital to fund operations through at least September 30, 2026.
• The company initiated its VANQUISH Phase 3 program for subcutaneous VK2735 in June 2025, comprising two studies targeting approximately 4,500 obese adults (VANQUISH-1) and 1,100 obese/overweight adults with type 2 diabetes (VANQUISH-2), with a primary endpoint of percent change in body weight at 78 weeks.
• Positive 52-week histologic data from the VOYAGE Phase 2b study of VK2809 in NASH/MASH patients showed up to 75% achieving NASH resolution with no worsening of fibrosis (p=0.0001) and up to 57% achieving 1-stage fibrosis improvement (p<0.05).
• Enrollment was completed for the Phase 2 clinical trial of the oral tablet formulation of VK2735 in March 2025, with initial results expected in the second half of 2025.
• Multi-year manufacturing agreements were signed with Corden Pharma Colorado, Inc. on March 10, 2025, securing dedicated capacity for VK2735 API and finished product (injectable and oral formulations), including annual capacity for 100 million autoinjectors, 100 million vial/syringe products, and over 1 billion oral tablets.
• The company announced a new Dual Amylin and Calcitonin Receptor Agonist (DACRA) program for obesity in 2024 and plans to file an Investigational New Drug (IND) application for this program in Q4 2025.
• Results from the Phase 1b clinical trial of VK0214 for X-ALD, announced in October 2024, showed the drug was safe, well-tolerated, and led to significant reductions in plasma VLCFAs; the company intends to pursue partnering or licensing opportunities for VK0214.
• A stock repurchase program of up to $250.0 million was authorized in February 2025, with no shares repurchased during the quarter ended June 30, 2025.
• The International Trade Commission (ITC) affirmed the Chief Administrative Law Judge's determination in favor of Viking on May 29, 2025, regarding trade secret misappropriation by Ascletis Defendants, including monetary and non-monetary sanctions.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company reported increased losses and cash burn, this is an expected consequence of advancing multiple promising drug candidates into late-stage clinical trials (VK2735 Phase 3, oral VK2735 Phase 2 completion) and securing critical manufacturing capacity. The strong 52-week histologic data for VK2809 and the favorable ITC legal ruling are significant de-risking events. The company maintains a strong cash runway, mitigating immediate funding concerns, though future capital raises are anticipated. The progress in the pipeline outweighs the increased expenses for a growth-oriented biopharma investor.

Positives

• Initiation of the VANQUISH Phase 3 program for subcutaneous VK2735 marks a significant advancement for the lead obesity candidate, moving closer to potential regulatory approval.
• Positive 52-week histologic data for VK2809 in NASH/MASH, demonstrating high rates of NASH resolution (up to 75%) and fibrosis improvement (up to 57%), positions it competitively in a high-need therapeutic area.
• Completion of enrollment for the oral VK2735 Phase 2 trial and expected results in H2 2025 indicate rapid progress for this potentially convenient formulation.
• Securing broad, multi-year manufacturing agreements for VK2735 API and finished product with CordenPharma ensures dedicated capacity for future commercialization, including 100 million autoinjectors and over 1 billion oral tablets annually.
• The new DACRA program for obesity, with preclinical data showing reduced food intake and positive metabolic profile, adds a promising early-stage asset to the pipeline.
• Positive Phase 1b results for VK0214 in X-ALD, showing VLCFA reduction, provide a basis for potential partnering or licensing in a rare disease with unmet need.
• The company maintains a strong liquidity position with $807.7 million in cash, cash equivalents, and short-term investments as of June 30, 2025, projected to fund operations through at least September 30, 2026.
• A favorable ruling from the International Trade Commission (ITC) against Ascletis Defendants for trade secret misappropriation, including monetary and non-monetary sanctions, strengthens the company's intellectual property position.

Negatives

• Net loss significantly increased to $65.561 million for Q2 2025 and $111.190 million for the six months ended June 30, 2025, reflecting higher operating expenses.
• Research and development expenses more than doubled, increasing by 153.1% in Q2 2025 and 112.1% for the six months, indicating a substantial increase in cash burn.
• General and administrative expenses also increased by over 40% in both periods, contributing to the overall loss.
• The company has not generated any revenue since its inception and does not expect to in the foreseeable future, relying entirely on financing to fund operations.
• Cash used in operating activities increased significantly to $99.392 million for the six months ended June 30, 2025, compared to $34.647 million in the prior year period.

Risks

• The company is a clinical-stage company with a limited operating history and is expected to incur significant operating losses for the foreseeable future.
• Substantial dependence on technologies licensed from Ligand Pharmaceuticals Incorporated, with potential harm to business if the license is lost or terminated.
• Success is dependent on one or more current drug candidates, with no certainty of regulatory approval or commercialization.
• Drug development efforts may not lead to commercial drugs due to safety/efficacy failures or inadequate financial resources.
• Delays in the commencement or completion of clinical trials could result in increased costs and delay strategic collaborations.
• Reliance on third parties (CROs, manufacturers) to conduct preclinical studies and clinical trials, with risks if they fail to perform or comply with regulations.
• Intense competition from other biopharmaceutical companies, with competitors potentially having faster approvals, more effective, better tolerated, or less costly drugs.
• Unstable market and economic conditions, including inflation and geopolitical conflicts, may adversely affect business and financial condition.
• Inability to obtain or maintain necessary rights to drug candidates through acquisitions and in-licenses.
• Drug candidates may cause undesirable side effects that could delay or prevent regulatory approval or commercialization.
• Efforts to discover drug candidates beyond current ones may not succeed, and recommended candidates may not advance to clinical trials.
• Resource allocation decisions may cause the company to fail to capitalize on more profitable product candidates or market opportunities.
• Need to raise additional capital in the future, which may be unavailable or cause dilution or significant restrictions on business operations.
• Manufacturing risks, including contamination, equipment failure, supply disruptions, and reliance on single-source suppliers.
• Failure of third-party manufacturers to provide sufficient quantities of drug product at acceptable quality levels or prices.
• Manufacturing facilities may not continue to meet regulatory requirements (cGMP).
• Any future collaboration arrangements may not be successful.
• Inability to develop own commercial organization or enter into agreements with third parties to sell and market drug candidates.
• Commercial success depends on market acceptance among physicians, patients, healthcare payors, and the medical community.
• Failure to obtain and sustain adequate reimbursement for potential products by third-party payors.
• Current and future legislation (e.g., Inflation Reduction Act, One Big Beautiful Bill Act) may increase the difficulty and cost of commercializing drug candidates and affect prices.
• Changes in government funding for regulatory agencies (FDA, SEC) could hinder their ability to perform normal business functions.
• Subject to fraud and abuse and similar laws and regulations, with potential for significant fines and penalties for noncompliance.
• Impact of actions by the current U.S. administration, including executive orders, policies, new legislation, and judicial decisions.
• Compliance with global privacy and data security requirements (GDPR, CCPA, CPRA) could result in additional costs and liabilities.
• Subject to U.S. and foreign anti-corruption, anti-money laundering, export control, and sanctions laws.
• Governments outside the U.S. tend to impose strict price controls.
• Failure to retain current senior management and scientific personnel or attract additional key personnel.
• Need to increase the size of the organization and successfully manage growth.
• Exposure to product liability, non-clinical, and clinical liability risks.
• Research and development activities involve hazardous materials, subject to regulation and potential liabilities.
• Reliance on information technology, with risks of failure, inadequacy, interruption, or cybersecurity incidents.
• Artificial intelligence presents risks and challenges, including security risks to confidential information and an uncertain regulatory environment.
• Employees and consultants may engage in misconduct or other improper activities.
• Business disruptions such as natural disasters or geopolitical conflicts could harm future revenues and financial condition.
• Strategic transactions could impact liquidity, increase expenses, and distract management.
• Employment agreements with officers and certain employees may require severance benefits in connection with a change in control.
• Ability to effectively monitor and respond to evolving expectations relating to sustainability (ESG) may impose unexpected costs or reputational harm.
• The market price of common stock may be highly volatile.
• An active trading market for common stock may not be sustained.
• Management owns a significant percentage of stock and can exert significant control over stockholder approval matters.
• Internal control over financial reporting may not meet Sarbanes-Oxley Act standards.
• Increased costs and management time due to public company compliance.
• Securities or industry analysts not publishing research, or publishing inaccurate or unfavorable research, could cause stock price and trading volume to decline.
• Sales of a substantial number of shares by existing stockholders or future issuances could cause stock price to fall.
• Management has broad discretion over the use of proceeds from prior financings and available cash.
• Risk of securities class action litigation.
• Ability to use net operating loss carryforwards may be subject to certain limitations under Section 382 of the Internal Revenue Code.
• Changes in tax laws could adversely affect business and financial condition.
• The company may never pay dividends on its common stock, limiting returns to stock appreciation.
• Provisions in charter documents and Delaware law could make it more difficult or expensive for a third party to acquire the company or change its board/management.
• Amended and restated bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain actions, potentially limiting stockholders' ability to obtain a favorable judicial forum.
• The timing and amount of any repurchases under the stock repurchase program are subject to uncertainties and the program may be suspended, modified, or discontinued.

Future Outlook

The company anticipates continued significant operating losses as it expands drug development activities, seeks potential partnering opportunities, and pursues regulatory approvals and commercialization for its drug candidates. Increased research and development expenses are expected as the VK2735, VK2809, and VK0214 programs advance, and additional programs are pursued. General and administrative expenses are also projected to increase to support these activities and public company compliance. The company believes its current cash, cash equivalents, and short-term investments are sufficient to fund operations through at least September 30, 2026, but will need to raise additional capital for future funding requirements.

Management Comments

• We expect that our ongoing research and development expenses will consist of costs incurred for the development of our drug candidates, including employeeand consultant-related expenses, expenses incurred under agreements with investigative sites and CROs, payments to third-party manufacturers, license fees, and facilities costs.
• We manage and prioritize our research and development expenses dynamically based on scientific data, probability of successful technical development and regulatory approval, market potential and unmet medical need, available human and capital resources and other considerations.
• We regularly review our research and development activities and, as necessary, reallocate resources among our program, product candidates and external opportunities that we believe will best support the long-term growth of our business.
• We expect that our general and administrative expenses will continue to increase in the future in order to support our expected increase in research and development activities, including increased salaries and other related costs, stock-based compensation and consulting fees for executive, finance, accounting and business development functions.
• We believe our cash, cash equivalents and short-term investments will be sufficient to fund our operations through at least September 30, 2026, which is more than one year after the date of our filing of this Form 10-Q.
• Our intent is to pursue partnering or licensing opportunities for VK0214 prior to conducting additional clinical studies.
• Our intent is to continue to pursue partnering or licensing opportunities for VK5211 prior to conducting additional clinical studies.
• We plan to file an investigational new drug application for our Dual Amylin and Calcitonin Receptor Agonist (DACRA) program in the fourth quarter of this year.

Industry Context

Viking Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically targeting metabolic and endocrine disorders. The initiation of Phase 3 trials for VK2735 places it in direct competition with established and emerging GLP-1/GIP agonists from major players like Novo Nordisk (Wegovy, Saxenda, CagriSema) and Eli Lilly (Zepbound, Orforglipron, Retatrutide), reflecting the intense focus on the lucrative obesity market. The positive 52-week histologic data for VK2809 positions it as a strong contender in the NASH/MASH space, where Madrigal Pharmaceuticals' Rezdiffra is currently the only approved therapy, highlighting a significant unmet medical need and market opportunity. The company's strategy to pursue partnering for VK0214 and VK5211 aligns with industry trends for smaller biotechs to de-risk assets and leverage larger partners' commercial capabilities for niche or earlier-stage programs. The increased R&D spend is typical for a company advancing multiple programs into later-stage clinical development, reflecting the high costs associated with large-scale trials and manufacturing scale-up.

Comparison to Industry Standards

• VK2735's Phase 2 results, showing up to 14.7% mean body weight reduction from baseline after 13 weeks, are competitive with leading GLP-1 agonists like Novo Nordisk's Wegovy (semaglutide), which demonstrated approximately 15% weight loss in its 68-week STEP 1 trial, and Eli Lilly's Zepbound (tirzepatide), which showed up to 20.9% weight loss in its 72-week SURMOUNT-1 trial. VK2735's oral formulation's 5.3% weight reduction over 28 days also shows promise for an oral option, a key differentiator in the market.
• VK2809's 52-week histologic data for NASH/MASH, with up to 75% of patients achieving NASH resolution with no worsening of fibrosis (p=0.0001) and up to 57% achieving 1-stage improvement in fibrosis with no worsening of NASH (p<0.05), compares favorably to Madrigal Pharmaceuticals' Rezdiffra (resmetirom). In its MAESTRO-NASH trial, Rezdiffra achieved NASH resolution with no worsening of fibrosis in 26-30% of patients and fibrosis improvement with no worsening of NASH in 23-27% of patients, suggesting VK2809 may offer superior efficacy.
• For X-ALD, VK0214's demonstrated reduction in plasma VLCFAs is a positive indicator in a disease with no approved oral treatments. While bluebird bio's elivaldogene autotemcel is approved for cerebral adrenoleukodystrophy (CALD), it is an invasive gene therapy, leaving a significant unmet need for non-invasive options like VK0214, particularly for the adrenomyeloneuropathy (AMN) form of X-ALD.

Legal Proceedings

• In December 2022, the company filed suit against Ascletis Bioscience Co., Ltd., Gannex Pharma Co., Ltd., Ascletis Pharmaceuticals Co., Ltd., Ascletis Pharma Inc., and Jinzi Jason Wu (Ascletis Defendants) in the Southern District of California, San Diego division, alleging violation of the Defend Trade Secrets Act, violation of the California Uniform Trade Secrets Act, breach of contract, breach of the implied covenant of good faith and fair dealing, and tortious interference with contract.
• In a related action, the company also filed suit against the same Ascletis Defendants in the International Trade Commission (ITC) for unlawful and unfair methods of competition, arising from alleged misappropriation of trade secrets.
• On October 3, 2024, the ITC's Chief Administrative Law Judge issued a Notice of his determination in favor of Viking, stating that Ascletis Defendants misappropriated trade secrets while under a Confidential Disclosure Agreement and engaged in discovery misconduct, warranting monetary and non-monetary sanctions.
• On May 29, 2025, the full ITC Commission affirmed the substantial majority of the ITC Chief Administrative Law Judge's determinations in favor of Viking, including monetary and non-monetary sanctions.
• The company plans to continue to vigorously pursue all legal remedies in these litigations, including through any appeals processes that the Ascletis Defendants may initiate.

Stakeholder Impact

• **Shareholders:** Increased R&D spend and net losses indicate continued investment in pipeline development, which could lead to long-term value creation if drug candidates succeed, but also implies continued dilution risk from future capital raises. The stock repurchase program could provide some support.
• **Employees:** Increased general and administrative expenses, including stock-based compensation and salaries, suggest continued investment in human capital. The company's growth plans will require hiring additional personnel.
• **Customers (future patients):** Advancement of VK2735 into Phase 3 and positive VK2809 data offer potential new treatment options for obesity and NASH/MASH, addressing significant unmet medical needs.
• **Suppliers/Partners:** Multi-year manufacturing agreements with CordenPharma indicate a strong, long-term relationship and commitment to scaling production for VK2735. Reliance on third-party CROs and manufacturers continues.
• **Creditors:** The strong cash and investment position provides a solid financial buffer, reducing immediate credit risk, but the ongoing losses and need for future capital raises highlight long-term funding requirements.

Next Steps

• Report initial results from the Phase 2 clinical trial of the oral tablet formulation of VK2735 in the second half of 2025.
• Continue the VANQUISH Phase 3 program for subcutaneous VK2735, with studies designed to assess efficacy and safety over 78 weeks.
• File an Investigational New Drug (IND) application for the Dual Amylin and Calcitonin Receptor Agonist (DACRA) program in the fourth quarter of 2025.
• Pursue partnering or licensing opportunities for VK0214 and VK5211 prior to conducting additional clinical studies.
• Vigorously pursue all legal remedies in the ongoing litigation against Ascletis Defendants, including through any appeals processes.

Key Dates

Recommendation

The company has achieved significant de-risking milestones in its pipeline, most notably the initiation of Phase 3 for VK2735, a highly anticipated obesity drug, and the release of compelling 52-week histologic data for VK2809 in NASH/MASH, which appears competitive with the only approved therapy. Securing multi-year manufacturing agreements for VK2735 is a crucial step towards commercialization. While losses have increased, this is a direct result of accelerating high-value clinical programs, which is a positive signal for a biopharma company. The current cash runway is sufficient for over a year, providing time to execute on these programs. The favorable ITC ruling also strengthens the company's intellectual property. For long-term investors with a tolerance for biopharma risk, these advancements suggest strong potential for future value creation, making it a compelling 'buy' at this stage of pipeline maturation.

Keywords

Biopharmaceutical, Metabolic Disorders, Endocrine Disorders, Obesity, NASH, MASH, X-ALD, GLP-1, GIP, Thyroid Hormone Receptor Beta, TR Beta, Dual Agonist, Clinical Trials, Phase 3, Phase 2, Drug Development, Biotech, SEC Filing, 10-Q, VKTX, VK2735, VK2809, VK0214, DACRA, Manufacturing Agreements, CordenPharma, Trade Secrets, Intellectual Property